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tine as for comparator. The price sensitivity analysis of comparators was done. The 
reassessment of CEA after price cut of comparators (up to—10%, due to international 
price referencing) has showed the positive results for agomelatine and robustness of 
previous price sensitivity analysis. CONCLUSIONS: The focus of the MoH drug 
policy is on more rational spendings , especially on reference pricing and HTA. There 
are ﬁrst results of these new procedures, where the real impact of the HTA in the 
decision processes is demonstrated. Agomelatin, a new agent in therapy of depression 
fulﬁlled, the necessary legislative conditions including pharmacoeconomic aspects to 
be listed in the positive reimbursement list.
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OBJECTIVES: To examine whether non-generic duloxetine and venlafaxine XR are 
essentially interchangeable in patients with major depressive disorder (MDD) or used 
selectively for patients with different treatment histories, costs, demographics, and 
comorbidities. METHODS: Using the US PharMetrics Database, we studied com-
mercially insured individuals aged 18–64 initiating treatment with duloxetine or ven-
lafaxine XR between July 2005 and July 2006, with q1 prior MDD diagnosis and 
continuous enrollment for 12 months prior to initiation date. Initiation was deﬁned 
as the ﬁrst use of either medication preceded by 3 months no prescription for or use 
of the same medication. Chi-square and logistic regression analysis of patients’ demo-
graphics, past-year medication use, and comorbidities were used to assess predictors 
of initiations with duloxetine versus venlafaxine XR. RESULTS: A total of 9641 
patients (73.6% female) initiated treatment with duloxetine and 8514 (71.5% female) 
with venlafaxine XR. Compared to venlafaxine XR patients, duloxetine patients were 
older (45 vs. 42.4 years), had q3 unique prior pain medications (25.5% vs. 15.6%), 
SSRIs (59.5% vs. 52.7%), TCAs (12.6% vs. 7.8%), analgesics (63.1% vs. 51.3%), 
anticonvulsants (30.1% vs. 17.9%), hypnotics (30.2% vs. 22.3%), and had q8 unique 
comorbid medical conditions (38.6% vs. 29.1%) and pain diagnoses (76.3% vs. 
67.8%) (all p-values 0.005). Logistic regression results revealed that 61% of dulox-
etine initiators and 61% of venlafaxine XR initiators were predictable from prior 
patient and treatment factors. The prior 6-month total health care costs were $1731 
higher for future duloxetine patients than for future venlafaxine XR patients, and 
despite higher subsequent pharmacy costs, total health care costs declined for both 
medications after treatment with each drug began. CONCLUSIONS: MDD patients 
treated with duloxetine tended to have a more complex and costly antecedent clinical 
presentation compared with venlafaxine XR-treated patients, suggesting physicians do 
not use the two medications interchangeably and both may have unique roles on 
formularies.
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OBJECTIVES: This retrospective study aimed to explore predictors of duloxetine 
versus other antidepressants for treating patients with major depressive disorder 
(MDD) in the Veterans Affairs (VA) health system. Duloxetine was not on the VA 
national drug formulary. METHODS: The electronic medical records from October 
2004 to October 2008 were extracted from the VA Veterans Integrated Service 
Network 16 data warehouse. All patients were treated with either duloxetine mono-
therapy (duloxetine) or other antidepressants (non-duloxetine) over the study period, 
with the ﬁrst dispense date of the index agent as the index date. All patients must 
have at least 1 prior MDD diagnosis (ICD-9-CM: 296.2 or 296.3), but no prior dia-
betes (ICD-9-CM: 250.xx) or bipolar disorder (ICD-9-CM: 296.4x-296.8x) diagnosis. 
Logistic regression was used to examine the predictors of treatment of duloxetine 
versus other antidepressants, controlling for demographics, comorbidities, prior 
opioid use, and pain level in the 12 months pre-index period. RESULTS: The logistic 
regression sample included 12,077 patients (duloxetine: n  448; non-duloxetine: n  
11,629). Patients who were female (odds ratio [OR]  3.15, 95% Conﬁdence Interval 
[CI]: 2.48–4.00), white (OR  1.48, CI: 1.15–1.91), with non-VA insurance (OR  
1.69, CI: 1.24–2.31), or prior emergency department (ED) visit (OR  1.64, CI: 
1.21–2.22) were more likely to use duloxetine. Patients comorbid with dyslipidemia, 
hypertension, or substance abuse were 1.60 (CI: 2.08–3.25), 0.35 (CI: 1.09–1.68), and 
0.41 (CI: 1.14–1.75) times more likely to use duloxetine. Prior short-acting and long-
acting opioid users were 3.32 (CI: 2.60–4.23) and 8.98 (CI: 6.95–11.60) times as likely 
to use duloxetine as those with no prior opioid use, respectively. Patients with self-
reported moderate or severe pain were 1.43 (CI: 1.07–1.90) or 1.50 (CI: 1.16–1.92) 
times as likely to use duloxetine as those with no pain. CONCLUSIONS: The VA 
patients who were treated with duloxetine appeared to have more ED visits, more 
comorbid conditions, prior substance abuse or opioid use, and higher pain levels.
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OBJECTIVES: To determine if patients are adherent with interferons used to treat 
patients with Multiple Sclerosis (MS), the optimal adherence rate to maximize clinical 
outcomes, and the impact of adherence on the number and severity of relapses. 
METHODS: A retrospective cohort study design was used. Pharmacy and medical 
claims data were extracted for 2006–2008. Adherence was measured using two stan-
dard methods for Medication Possession Ratio (MPR), one that incorporates persis-
tence and one that does not. Threshold analyses were run to determine an optimal 
adherence rate to minimize relapses. Patients were considered adherent if they met a 
predeﬁned standard cut-off point and reanalyzed with the newly determined cut point. 
The number and severity of relapses were measured for each patient year, with 2008 
being the critical outcomes point. A series of regression models were used to assess 
the impact of adherence on the number and severity of relapses. RESULTS: A total 
of 3590 patients were included in the study. Based on the method, the average MPR 
varied between 77.6% and 89.8%. The threshold analysis determined that the optimal 
adherence rate is around 85%. Patients receiving interferon through a specialty phar-
macy are more adherent than those who did not. Patients who were classiﬁed as 
adherent through 2007 had a signiﬁcantly lower risk of relapse in 2008. Patients who 
were adherent also had a signiﬁcantly lower risk of severe relapse than those who 
were non-adherent. Complete MPRs, adherence rates, individual year descriptives, and 
inferential statistics will be included in the presentation. CONCLUSIONS: Patients 
with MS are generally adherent with their interferon therapy, although opportunities 
for improvement exist. Patients who receive special pharmacy services are more adher-
ent than those who receive standard retail services. The effect of adherence on the 
number and severity of relapses demonstrated the positive impact of interferons for 
MS treatment.
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OBJECTIVES: The aim of this study was to evaluate the efﬁcacy for ﬁve FDA 
approved drugs for Alzheimer’s disease. METHODS: MEDLINE and the International 
Pharmaceutical Abstracts databases were searched for studies addressing functional 
outcomes with Alzheimer’s disease. The primary outcome was cognitive efﬁcacy and 
must have been measured on a validated scale. To report one consistent scale value, 
values were transformed into z-scores to obtain a dichotomized output, categorized 
as either improvement or a lack therof in treatment. Odds ratios were calculated for 
success for each drug treatment. Winbugs version 1.4 statistical software was used to 
conduct a mixed treatment comparisons Bayesian analysis along with a sub-analysis 
to examine whether or not the cognitive measurement scale used in the studies effects 
the ranking of drug treatments. RESULTS: The mixed treatment comparisons results 
showed that galantamine OR  2.518E7, 95%CRI: 447,300–7.034E9 was highly 
favored above all other Alzheimer’s treatments, followed by donepezil OR  1557, 
95%CRI: 315.4–8341, tacrine OR  212.8, 95%CRI: 28.47–1604, rivastigmine OR 
 23.57, 95%CRI: 5.397–104.8, memantine OR  3.775, 95%CRI: 0.639–23.09 
compared to placebo. The sub-analysis also showed that galantamine OR  2.832E7, 
95%CRI: 483900–2.326E10 as highly favored, but yielded slightly different results 
with tacrine OR  1434, 95%CRI: 148.2–15830 ahead of donepezil OR  471.2, 
95%CRI: 83.48–2935 in ranking, followed by rivastigmine OR  19.54, 95%CRI: 
4.781–83.19 and memantine OR  2.836, 95%CRI: 0.2196–37.96. This analysis 
removed the eight studies that did not use the ADAS-Cog measurement scale, suggest-
ing that the selection of the cognitive measurement scale changes the ranking of drug 
treatments. Odds ratios for galantamine were high due to the favorable response (q95) 
for the drug. The severity of Alzheimer’s disease was not taken into account in this 
study. CONCLUSIONS: The consistency between drugs in terms of cognitive efﬁcacy 
is present in all ﬁve drugs; all demonstrating effectiveness over placebo. Future 
research in this area is needed, including clinical studies comparing the agents 
directly.
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OBJECTIVES: The aim of this meta-analysis was to evaluate the efﬁcacy and tolerabil-
ity of Natalizumab in relapsing multiple sclerosis (MS). METHODS: “Mean change 
in Expanded Disability Status Scale (EDDS)”, “number of patients with at least one 
relapse”, and “number of patients with at least one new gadolinium (Gd)-enhancing 
lesion” were the key outcomes of interest for assessment of efﬁcacy. “Any adverse 
events”, “serious adverse events”, “death”, and “withdrawal because of adverse 
events” were the key outcomes for tolerability. RESULTS: Amongst existing trials, 
four randomized placebo controlled clinical trials met our criteria and were included. 
